Prodrugs and medical uses thereof
AssigneeConvert Pharmaceuticals S.A.
InventorsArne Heyerick, Sofie Deschoemaeker, Sophie Thiolloy, Dominique Tersago, Philippe Lambin
Life of this patent
Estimating the term…
Abstract
The invention relates to nitrogen mustards bearing substituted piperazine carboxamide and their corresponding pharmaceutically acceptable salts as cytotoxic agents that target tumours and methods of use thereof, alone or in combination with other cancer treatments.
Claims18
A method for the treatment of a solid, metastatic cancer affecting a Human patient, wherein said solid cancer is selected from a group consisting of breast cancer and pancreatic cancer, comprising a step of administering an effective amount of 2-((2-bromoethyl) (5-(4-ethylpiperazine-1-carbonyl)-2-(methylsulfonyl)-4-nitrophenyl)amino)ethyl methanesulfonate or a pharmaceutically acceptable salt, solvate, or stereoisomer of said compound, wherein presence of a hypoxia gene expression signature has been assessed and confirmed in said solid metastatic cancer, and wherein said patient has previously been treated with a radiotherapy, chemotherapy, and/or an immunotherapy.
A method for the treatment of a solid, metastatic cancer affecting a Human patient comprising:
- selecting said solid metastatic cancer from a group consisting of breast cancer and pancreatic cancer;
- assessing a homologous recombination and DNA repair mechanism status of said solid cancer and confirming said solid cancer has a hypoxia gene expression signature;
- and
- administering an effective amount of 2-((2-bromoethyl) (5-(4-ethylpiperazine-1-carbonyl)-2-(methylsulfonyl)-4-nitrophenyl)amino)ethyl methanesulfonate or a pharmaceutically acceptable solvate, or stereoisomer thereof in said cancer.
Dependencies are inferred from the claim text.